-The Hindu blog   Data from the latest Transparency International report throws up few surprises as far as India is concerned. Virtually no key institution or sector in India is seen as being free from corruption in the latest survey of the international anti-corruption watchdog Transparency International, which, in its report 'Global Corruption Barometer 2013' states that bribe paying levels remain "very high" worldwide. Data from the report offers interesting insights into global corruption...

-The Hindu There has been no public debate on the level of watch citizens can be put through, and on what the red lines should be while using intrusive mechanisms The tussle between government agencies' need for a better, faster and real-time interception, surveillance and monitoring mechanism through the Central Monitoring System (CMS), on the one hand, and demands by privacy, civil rights and free speech activists, for ensuring higher privacy for...

-The Times of India NEW DELHI: It is yet another dubious distinction that Delhi Police could have done without. According to the National Crime Records Bureau (NCRB) report for 2012, Delhi (in UT/States) has reported the highest number of complaints made against per 100 policemen (17), highest in the country. It is followed by Madhya Pradesh (14.7) and Chandigarh (10.1). The national average was just 3.7 in 2011. This is the...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...